MeMed logo
page-image.jpg

MeMed’s Presentation Theater at 

MeMed is transforming patient care by listening to the immune system and turning host response signals into clinical action.

Watch theater presentation

gruppe.jpg
Dr. Eran Eden

Dr. Eran Eden

Dr. Eran Eden is the Co-founder and CEO of MeMed since its inception in 2009. He lead MeMed from an idea to a rapidly growing company that is pioneering the field of host-response technologies.

fever-dilemma.png

Dr. Debra Goff

Dr. Goff is an Infectious Diseases Specialist pharmacist at The Ohio State University Wexner Medical Center and global antibiotic stewardship expert.

Is it a bacterial or viral infection? Using host-response technologies to decode the immune system and aid antibiotic stewardship

What would your practice look like if you had a 15-minute test that could differentiate between a bacterial and viral infection? MeMed BV® is the first rapid and accurate (blinded and external validation) host-response technology for distinguishing between bacterial and viral infections in under 15 minutes, and it is changing the paradigm in infectious disease patient management.

A doctor treats children

About MeMed

At MeMed, a leader in host response technologies, we decode the body's complex signals into simple insights that improve people's lives. By leveraging our expertise in host-response profiling and machine-learning algorithms, we are creating a portfolio of tests that address tough clinical dilemmas.

 

Importantly, with the support of public and private partnerships, we have developed a point-of-need, rapid measurement platform called MeMed Key® to ensure timely availability of these novel tests during the clinician’s decision-making workflow.

A girl talking on the phone

Contact us

 

Come join MeMed's Presentation Theater at IDWeek 

Sheldon-L.-Kaplan.png

Sheldon L. Kaplan, MD

Head, Pediatric Infectious Disease Section, Baylor College of Medicine

arrow

New Developments in Infectious Diseases Diagnostics:

112 - A Rapid Host-Protein Signature Based on TNF-related Apoptosis-Induced Ligand (TRAIL), Interferon Gamma Induced Protein-10 (IP-10) and C-Reactive Protein (CRP) Accurately Differentiates Between Bacterial and Viral Infection in Febrile Children: Apollo Sub-Study.

Alon-Angel.png

Alon Angel

International Investigator Award Product Associate, MeMed

arrow

COVID-19 Complications, Co-infections and Clinical Outcomes: 

32 - Host Immune-Protein Signature Combining TRAIL, IP-10 and CRP for Early and Accurate Prediction of Severe COVID-19 Outcome